Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction.

Nepper-Christensen L, Høfsten DE, Helqvist S, Lassen JF, Tilsted HH, Holmvang L, Pedersen F, Joshi F, Sørensen R, Bang L, Bøtker HE, Terkelsen CJ, Maeng M, Jensen LO, Aarøe J, Kelbæk H, Køber L, Engstrøm T, Lønborg J.

Heart. 2019 Jul 17. pii: heartjnl-2019-314952. doi: 10.1136/heartjnl-2019-314952. [Epub ahead of print]

PMID:
31315939
2.

Characterisation of lesions undergoing ischaemia-driven revascularisation after complete revascularisation versus culprit lesion only in patients with STEMI and multivessel disease: a DANAMI-3-PRIMULTI substudy.

De Backer O, Lønborg J, Helqvist S, Warnøe J, Kløvgaard L, Holmvang L, Pedersen F, Tilsted HH, Raungaard B, Jørgensen E, Køber L, Høfsten DE, Kelbæk H, Engstrøm T.

EuroIntervention. 2019 Jun 20;15(2):172-179. doi: 10.4244/EIJ-D-18-00766.

3.

Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients.

Sadjadieh G, Engstrøm T, Høfsten DE, Helqvist S, Køber L, Pedersen F, Laursen PN, Andersson HB, Nepper-Christensen L, Clemmensen P, Sørensen R, Jørgensen E, Saunamäki K, Tilsted HH, Kelbæk H, Holmvang L.

Am J Cardiol. 2018 Oct 15;122(8):1287-1296. doi: 10.1016/j.amjcard.2018.07.008. Epub 2018 Jul 19.

PMID:
30115422
4.

Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study.

Laursen PN, Holmvang L, Lønborg J, Køber L, Høfsten DE, Helqvist S, Clemmensen P, Kelbæk H, Jørgensen E, Lassen JF, Pedersen F, Høi-Hansen T, Therkelsen CJ, Tilsted HH, Jensen LO, Nepper-Christensen L, Sadjadieh G, Engstrøm T.

Am Heart J. 2018 Oct;204:128-138. doi: 10.1016/j.ahj.2018.05.018. Epub 2018 Aug 10.

PMID:
30103092
5.

MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy.

Falkentoft AC, Rørth R, Iversen K, Høfsten DE, Kelbæk H, Holmvang L, Frydland M, Schoos MM, Helqvist S, Axelsson A, Clemmensen P, Jørgensen E, Saunamäki K, Tilsted HH, Pedersen F, Torp-Pedersen C, Kofoed KF, Goetze JP, Engstrøm T, Køber L.

J Am Heart Assoc. 2018 May 18;7(11). pii: e008123. doi: 10.1161/JAHA.117.008123.

6.

Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial.

Engstrøm T, Nepper-Christensen L, Helqvist S, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamaki K, Tilsted HH, Steensberg A, Fabricius S, Mouritzen U, Vejlstrup N, Ahtarovski KA, Göransson C, Bertelsen L, Kyhl K, Olivecrona G, Kelbæk H, Lassen JF, Køber L, Lønborg J.

Heart. 2018 Oct;104(19):1593-1599. doi: 10.1136/heartjnl-2017-312774. Epub 2018 Mar 30.

PMID:
29602883
7.

Relation of Bleeding Events to Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention (a DANAMI-3 Substudy).

Sadjadieh G, Engstrøm T, Helqvist S, Høfsten DE, Køber L, Pedersen F, Laursen PN, Nepper-Christensen L, Clemmensen P, Møller-Helgestad OK, Sørensen R, Ravkilde J, Terkelsen CJ, Jørgensen E, Saunamäki K, Tilsted HH, Kelbæk H, Holmvang L.

Am J Cardiol. 2018 Apr 1;121(7):781-788. doi: 10.1016/j.amjcard.2017.12.019. Epub 2018 Jan 12.

PMID:
29402421
8.

Association of common genetic variants related to atrial fibrillation and the risk of ventricular fibrillation in the setting of first ST-elevation myocardial infarction.

Jabbari R, Jabbari J, Glinge C, Risgaard B, Sattler S, Winkel BG, Terkelsen CJ, Tilsted HH, Jensen LO, Hougaard M, Haunsø S, Engstrøm T, Albert CM, Tfelt-Hansen J.

BMC Med Genet. 2017 Nov 21;18(1):138. doi: 10.1186/s12881-017-0497-1.

9.

Denmark: coronary and structural heart interventions from 2010 to 2015.

Tilsted HH, Ahlehoff O, Terkelsen CJ, Pedersen F, Özcan C, Jørgensen TH, Nielsen-Kudsk JE, Ravkilde J, Nissen H, Pedersen SA, Havndrup O, Lassen JF.

EuroIntervention. 2017 May 15;13(Z):Z17-Z20. doi: 10.4244/EIJ-D-16-00857.

10.

Fractional Flow Reserve-Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment-Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization).

Lønborg J, Engstrøm T, Kelbæk H, Helqvist S, Kløvgaard L, Holmvang L, Pedersen F, Jørgensen E, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L, Høfsten DE; DANAMI 3-PRIMULTI Investigators.

Circ Cardiovasc Interv. 2017 Apr;10(4). pii: e004460. doi: 10.1161/CIRCINTERVENTIONS.116.004460.

PMID:
28404623
11.

Effect of Ischemic Postconditioning During Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.

Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Clemmensen P, Holmvang L, Jørgensen E, Pedersen F, Saunamaki K, Ravkilde J, Tilsted HH, Villadsen A, Aarøe J, Jensen SE, Raungaard B, Bøtker HE, Terkelsen CJ, Maeng M, Kaltoft A, Krusell LR, Jensen LO, Veien KT, Kofoed KF, Torp-Pedersen C, Kyhl K, Nepper-Christensen L, Treiman M, Vejlstrup N, Ahtarovski K, Lønborg J, Køber L; Third Danish Study of Optimal Acute Treatment of Patients With ST Elevation Myocardial Infarction–Ischemic Postconditioning (DANAMI-3–iPOST) Investigators.

JAMA Cardiol. 2017 May 1;2(5):490-497. doi: 10.1001/jamacardio.2017.0022.

12.

A Common Variant in SCN5A and the Risk of Ventricular Fibrillation Caused by First ST-Segment Elevation Myocardial Infarction.

Jabbari R, Glinge C, Jabbari J, Risgaard B, Winkel BG, Terkelsen CJ, Tilsted HH, Jensen LO, Hougaard M, Haunsø S, Engstrøm T, Albert CM, Tfelt-Hansen J.

PLoS One. 2017 Jan 13;12(1):e0170193. doi: 10.1371/journal.pone.0170193. eCollection 2017.

13.

Prognostic assessment of stable coronary artery disease as determined by coronary computed tomography angiography: a Danish multicentre cohort study.

Nielsen LH, Bøtker HE, Sørensen HT, Schmidt M, Pedersen L, Sand NP, Jensen JM, Steffensen FH, Tilsted HH, Bøttcher M, Diederichsen A, Lambrechtsen J, Kristensen LD, Øvrehus KA, Mickley H, Munkholm H, Gøtzsche O, Husain M, Knudsen LL, Nørgaard BL.

Eur Heart J. 2017 Feb 7;38(6):413-421. doi: 10.1093/eurheartj/ehw548.

PMID:
27941018
14.

Bleeding episodes in "complete, staged" versus "culprit only" revascularisation in patients with multivessel disease and ST-segment elevation myocardial infarction: a DANAMI-3-PRIMULTI substudy.

Sadjadieh G, Engstrøm T, Helqvist S, Høfsten DE, Køber L, Pedersen F, Clemmensen P, Jørgensen E, Saunamäki K, Tilsted HH, Kelbæk H, Holmvang L.

EuroIntervention. 2016 Nov 20;12(10):1231-1238. doi: 10.4244/EIJV12I10A203.

15.

Danish trends in pharmacotherapy, comorbidities, and demographics in patients referred for coronary angiography: what changed during a decade?

Jørgensen ME, Andersson C, Olsen AM, Juel K, Mortensen PE, Jørgensen E, Tilsted HH, von Kappelgaard LM, Torp-Pedersen C, Gislason GH.

Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):157-65. doi: 10.1093/ehjcvp/pvv005. Epub 2015 Feb 24.

PMID:
27533989
16.

Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.

Jensen LO, Thayssen P, Maeng M, Ravkilde J, Krusell LR, Raungaard B, Junker A, Terkelsen CJ, Veien KT, Villadsen AB, Kaltoft A, Tilsted HH, Hansen KN, Aaroe J, Kristensen SD, Hansen HS, Jensen SE, Madsen M, Bøtker HE, Berencsi K, Lassen JF, Christiansen EH.

Circ Cardiovasc Interv. 2016 Jul;9(7). pii: e003610. doi: 10.1161/CIRCINTERVENTIONS.115.003610.

PMID:
27412869
17.

Invasive angiography and revascularization in patients with stable angina following prior coronary artery bypass grafting: Results from the East Denmark heart registry.

Joshi FR, Biasco L, Pedersen F, Holmvang L, Helqvist S, Tilsted HH, Abildgaard U, Kelbaek H, Lassen JF, Jørgensen E, De Backer O, Engstrøm T.

Catheter Cardiovasc Interv. 2017 Feb 15;89(3):341-349. doi: 10.1002/ccd.26598. Epub 2016 May 24.

PMID:
27219901
18.

Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial.

Kelbæk H, Høfsten DE, Køber L, Helqvist S, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, De Backer O, Bang LE, Kofoed KF, Lønborg J, Ahtarovski K, Vejlstrup N, Bøtker HE, Terkelsen CJ, Christiansen EH, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Jensen LO, Clemmensen P, Grande P, Madsen JK, Torp-Pedersen C, Engstrøm T.

Lancet. 2016 May 28;387(10034):2199-206. doi: 10.1016/S0140-6736(16)30072-1. Epub 2016 Apr 3.

PMID:
27053444
19.

Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.

Jensen LO, Thayssen P, Christiansen EH, Maeng M, Ravkilde J, Hansen KN, Hansen HS, Krusell L, Kaltoft A, Tilsted HH, Berencsi K, Junker A, Lassen JF; SORT OUT IV Investigators.

J Am Coll Cardiol. 2016 Feb 23;67(7):751-62. doi: 10.1016/j.jacc.2015.11.051.

20.

Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial.

Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L; DANAMI-3—PRIMULTI Investigators.

Lancet. 2015 Aug 15;386(9994):665-71.

PMID:
26347918
21.

Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction.

Jensen LO, Terkelsen CJ, Horváth-Puhó E, Tilsted HH, Maeng M, Junker A, Lassen JF, Thuesen L, Sørensen HT, Thayssen P.

Am Heart J. 2015 Jul;170(1):70-8. doi: 10.1016/j.ahj.2015.03.020. Epub 2015 Apr 2.

PMID:
26093866
22.

Decreased patency rates following endoscopic vein harvest in coronary artery bypass surgery.

Andreasen JJ, Vadmann H, Oddershede L, Tilsted HH, Frøkjær JB, Jensen SE.

Scand Cardiovasc J. 2015;49(5):286-92.

PMID:
26053411
23.

Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.

De Backer O, Ratcovich H, Biasco L, Pedersen F, Helqvist S, Saunamäki K, Tilsted HH, Clemmensen P, Olivecrona G, Kelbaek H, Jørgensen E, Engstrøm T, Holmvang L.

Thromb Haemost. 2015 Aug 31;114(3):623-31. doi: 10.1160/TH15-01-0026. Epub 2015 May 21.

PMID:
25994355
24.

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: Ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only: Rationale and design of the DANAMI 3 trial program.

Høfsten DE, Kelbæk H, Helqvist S, Kløvgaard L, Holmvang L, Clemmensen P, Torp-Pedersen C, Tilsted HH, Bøtker HE, Jensen LO, Køber L, Engstrøm T; DANAMI 3 Investigators.

Am Heart J. 2015 May;169(5):613-21. doi: 10.1016/j.ahj.2015.02.004. Epub 2015 Feb 14.

PMID:
25965708
25.

To Aspirate or Not to Aspirate: That Is the Question.

Tilsted HH, Olivecrona GK.

JACC Cardiovasc Interv. 2015 Apr 20;8(4):585-7. doi: 10.1016/j.jcin.2015.01.014. No abstract available.

26.

Underuse of an invasive strategy for patients with diabetes with acute coronary syndrome: a nationwide study.

Gustafsson I, Hvelplund A, Hansen KW, Galatius S, Madsen M, Jensen JS, Tilsted HH, Terkelsen CJ, Jensen LO, Jørgensen E, Madsen JK, Abildstrøm SZ.

Open Heart. 2015 Feb 6;2(1):e000165. doi: 10.1136/openhrt-2014-000165. eCollection 2015.

27.

The Western Denmark Cardiac Computed Tomography Registry: a review and validation study.

Nielsen LH, Nørgaard BL, Tilsted HH, Sand NP, Jensen JM, Bøttcher M, Diederichsen AC, Lambrechtsen J, Kristensen LD, Mickley H, Munkholm H, Gøtzsche O, Knudsen LL, Bøtker HE, Pedersen L, Schmidt M.

Clin Epidemiol. 2014 Dec 31;7:53-64. doi: 10.2147/CLEP.S73728. eCollection 2015. Review.

28.

A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).

Maeng M, Baranauskas A, Christiansen EH, Kaltoft A, Holm NR, Krusell LR, Ravkilde J, Tilsted HH, Thayssen P, Jensen LO.

Catheter Cardiovasc Interv. 2015 Dec 1;86(7):1161-7. doi: 10.1002/ccd.25875. Epub 2015 May 6.

PMID:
25640050
29.

Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial.

Raungaard B, Jensen LO, Tilsted HH, Christiansen EH, Maeng M, Terkelsen CJ, Krusell LR, Kaltoft A, Kristensen SD, Bøtker HE, Thuesen L, Aarøe J, Jensen SE, Villadsen AB, Thayssen P, Veien KT, Hansen KN, Junker A, Madsen M, Ravkilde J, Lassen JF; Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT).

Lancet. 2015 Apr 18;385(9977):1527-35. doi: 10.1016/S0140-6736(14)61794-3. Epub 2015 Jan 16. Erratum in: Lancet. 2015 Apr 18;385(9977):1510.

PMID:
25601789
30.

Incidence and risk factors of ventricular fibrillation before primary angioplasty in patients with first ST-elevation myocardial infarction: a nationwide study in Denmark.

Jabbari R, Engstrøm T, Glinge C, Risgaard B, Jabbari J, Winkel BG, Terkelsen CJ, Tilsted HH, Jensen LO, Hougaard M, Chiuve SE, Pedersen F, Svendsen JH, Haunsø S, Albert CM, Tfelt-Hansen J.

J Am Heart Assoc. 2015 Jan 5;4(1):e001399. doi: 10.1161/JAHA.114.001399. Erratum in: J Am Heart Assoc. 2015 Jul;4(7). pii: e000738. doi: 10.1161/JAHA.115.000738.

31.

Long-term outcome of sirolimus-eluting and zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a Danish organization for randomized trials on clinical outcome III substudy).

Olesen KK, Tilsted HH, Jensen LO, Kaltoft A, Krusell LR, Ravkilde J, Christiansen EH, Madsen M, Thayssen P, Sørensen HT, Lassen JF, Maeng M.

Am J Cardiol. 2015 Feb 1;115(3):298-302. doi: 10.1016/j.amjcard.2014.10.038. Epub 2014 Nov 11.

PMID:
25499925
32.

Coronary computed tomography angiography without significant stenosis predicts favourable three-year prognosis.

Kristiansen JM, Zaremba T, Johansen MB, Tilsted HH, Jensen SE.

Dan Med J. 2014 Aug;61(8):A4884.

PMID:
25162443
33.

Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.

Thim T, Johansen MB, Chisholm GE, Schmidt M, Kaltoft A, Sørensen HT, Thuesen L, Kristensen SD, Bøtker HE, Krusell LR, Lassen JF, Thayssen P, Jensen LO, Tilsted HH, Maeng M.

BMC Cardiovasc Disord. 2014 Aug 13;14:100. doi: 10.1186/1471-2261-14-100.

34.

Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial.

Jensen LO, Thayssen P, Maeng M, Christiansen EH, Ravkilde J, Hansen KN, Kaltoft A, Tilsted HH, Madsen M, Lassen JF; Scandinavian Organization for Randomized Trials With Clinical Outcome SORT OUT IV Investigators.

JACC Cardiovasc Interv. 2014 Aug;7(8):840-8. doi: 10.1016/j.jcin.2014.02.014. Epub 2014 Jul 30.

35.

24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis.

Würtz M, Hvas AM, Jensen LO, Kaltoft AK, Tilsted HH, Kristensen SD, Grove EL.

Int J Cardiol. 2014 Aug 1;175(2):274-9. doi: 10.1016/j.ijcard.2014.05.013. Epub 2014 May 16.

PMID:
24861258
36.

Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.

Maeng M, Tilsted HH, Jensen LO, Krusell LR, Kaltoft A, Kelbæk H, Villadsen AB, Ravkilde J, Hansen KN, Christiansen EH, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Thuesen L, Madsen M, Thayssen P, Sørensen HT, Lassen JF.

Lancet. 2014 Jun 14;383(9934):2047-2056. doi: 10.1016/S0140-6736(14)60405-0. Epub 2014 Mar 14.

PMID:
24631162
37.

Long-term outcome following percutaneous coronary intervention with drug-eluting stents compared with bare-metal stents in saphenous vein graft lesions: from Western Denmark Heart Registry.

Hougaard M, Thayssen P, Kaltoft A, Tilsted HH, Maeng M, Lassen JF, Thuesen L, Okkels Jensen L.

Catheter Cardiovasc Interv. 2014 Jun 1;83(7):1035-42. doi: 10.1002/ccd.25279. Epub 2013 Dec 5.

PMID:
24311384
38.

Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology.

Thuesen L, Jensen LO, Tilsted HH, Mæng M, Terkelsen C, Thayssen P, Ravkilde J, Christiansen EH, Bøtker HE, Madsen M, Lassen JF.

Clin Epidemiol. 2013 Sep 19;5:357-61. doi: 10.2147/CLEP.S44651. eCollection 2013.

39.

Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial.

Antonsen L, Thayssen P, Hansen HS, Maeng M, Tilsted HH, Bøtker HE, Ravkilde J, Madsen M, Sørensen HT, Thuesen L, Lassen JF, Jensen LO.

EuroIntervention. 2014 Jun;10(2):212-23. doi: 10.4244/EIJV10I2A35.

40.

Employment status 1 year after out-of-hospital cardiac arrest in comatose patients treated with therapeutic hypothermia.

Kragholm K, Skovmoeller M, Christensen AL, Fonager K, Tilsted HH, Kirkegaard H, DE Haas I, Rasmussen BS.

Acta Anaesthesiol Scand. 2013 Aug;57(7):936-43. doi: 10.1111/aas.12142. Epub 2013 Jun 10.

PMID:
23750664
41.

Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).

Holmvang L, Kelbæk H, Kaltoft A, Thuesen L, Lassen JF, Clemmensen P, Kløvgaard L, Engstrøm T, Bøtker HE, Saunamäki K, Krusell LR, Jørgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Køber L, Kofoed KF, Terkelsen CJ, Helqvist S.

JACC Cardiovasc Interv. 2013 Jun;6(6):548-53. doi: 10.1016/j.jcin.2012.12.129. Epub 2013 May 15.

42.

[No need for decentralized PCI now].

Tilsted HH.

Ugeskr Laeger. 2013 Feb 4;175(6):378-9. Danish. No abstract available.

PMID:
23530281
43.

Deferred stent implantation in patients with ST-segment elevation myocardial infarction: a pilot study.

Kelbæk H, Engstrøm T, Ahtarovski KA, Lønborg J, Vejlstrup N, Pedersen F, Holmvang L, Helqvist S, Saunamäki K, Jørgensen E, Clemmensen P, Kløvgaard L, Tilsted HH, Raungaard B, Ravkilde J, Aaroe J, Eggert S, Køber L.

EuroIntervention. 2013 Feb 22;8(10):1126-33. doi: 10.4244/EIJV8I10A175.

44.

Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.

Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, Kaltoft A, Maeng M, Kristensen SD, Bøtker HE, Terkelsen CJ, Villadsen AB, Ravkilde J, Aarøe J, Madsen M, Thuesen L, Lassen JF; Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V investigators.

Lancet. 2013 Feb 23;381(9867):661-9. doi: 10.1016/S0140-6736(12)61962-X. Epub 2013 Jan 30. Erratum in: Lancet. 2013 Jul 27;382(9889):310. Noergaard, Bjarne Linde [corrected to Norgaard, Bjarne Linde].

PMID:
23374649
45.

Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease.

Azimi A, Charlot MG, Torp-Pedersen C, Gislason GH, Køber L, Jensen LO, Thayssen P, Ravkilde J, Tilsted HH, Lassen JF, Thuesen L.

Heart. 2013 May;99(9):655-60. doi: 10.1136/heartjnl-2012-303066. Epub 2013 Jan 18.

PMID:
23335496
46.

Sex- and age-related differences in clinical outcome after primary percutaneous coronary intervention.

Jakobsen L, Niemann T, Thorsgaard N, Nielsen TT, Thuesen L, Lassen JF, Jensen LO, Thayssen P, Ravkilde J, Tilsted HH, Mehnert F, Johnsen SP.

EuroIntervention. 2012 Dec 20;8(8):904-11. doi: 10.4244/EIJV8I8A139.

47.

[The Danish Heart Registry].

Zwisler AD, Tilsted HH, Berg H, Mortensen PE.

Ugeskr Laeger. 2012 Oct 15;174(42):2523. Danish. No abstract available.

PMID:
23079426
48.

Dimensions of socioeconomic status and clinical outcome after primary percutaneous coronary intervention.

Jakobsen L, Niemann T, Thorsgaard N, Thuesen L, Lassen JF, Jensen LO, Thayssen P, Ravkilde J, Tilsted HH, Mehnert F, Johnsen SP.

Circ Cardiovasc Interv. 2012 Oct;5(5):641-8. doi: 10.1161/CIRCINTERVENTIONS.112.968271. Epub 2012 Oct 2.

PMID:
23031837
49.

Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry.

Maeng M, Jensen LO, Kaltoft A, Tilsted HH, Christiansen EH, Thayssen P, Madsen M, Sørensen HT, Lassen JF, Thuesen L.

BMC Cardiovasc Disord. 2012 Oct 2;12:84. doi: 10.1186/1471-2261-12-84.

50.

The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation.

Thayssen P, Jensen LO, Lassen JF, Tilsted HH, Kaltoft A, Christiansen EH, Hansen KN, Ravkilde J, Maeng M, Krusell L, Madsen M, Sørensen HT, Thuesen L; Western Denmark Heart Registry.

EuroIntervention. 2012 Sep;8(5):591-8. doi: 10.4244/EIJV8I5A91.

Supplemental Content

Loading ...
Support Center